Relative Bioavailability of the LY3009104 Free Base Test Formulation Compared to the Reference Phosphate Salt Formulation and the Effect of Food on the Bioavailability of the Test Formulation in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 12 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2011 Planned end date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 03 Aug 2011 Planned End Date changed from 1 Sep 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.